Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

The Challenging Experience Questionnaire: Characterization of challenging experiences with psilocybin mushrooms
Frederick S. Barrett, Matthew P. Bradstreet, Jeannie‐Marie Leoutsakos, et al.
Journal of Psychopharmacology (2016) Vol. 30, Iss. 12, pp. 1279-1295
Open Access | Times Cited: 264

Showing 26-50 of 264 citing articles:

Acute Adverse Effects of Therapeutic Doses of Psilocybin
Akhila Yerubandi, Jennifer E. Thomas, N. M. Mahmudul Alam Bhuiya, et al.
JAMA Network Open (2024) Vol. 7, Iss. 4, pp. e245960-e245960
Open Access | Times Cited: 20
Psychiatric risks for worsened mental health after psychedelic use
Alessia Marrocu, Hannes Kettner, Brandon Weiss, et al.
Journal of Psychopharmacology (2024) Vol. 38, Iss. 3, pp. 225-235
Open Access | Times Cited: 17
Potential therapeutic effects of an ayahuasca-inspired N,N-DMT and harmine formulation: a controlled trial in healthy subjects
Helena D. Aicher, Michael J. Mueller, Dario A. Dornbierer, et al.
Frontiers in Psychiatry (2024) Vol. 14
Open Access | Times Cited: 16
Single-Dose Psilocybin for Depression With Severe Treatment Resistance: An Open-Label Trial
Scott T. Aaronson, Andrew van der Vaart, Tammy Miller, et al.
American Journal of Psychiatry (2025) Vol. 182, Iss. 1, pp. 104-113
Closed Access | Times Cited: 2
Current perspectives on psychedelic therapy: use of serotonergic hallucinogens in clinical interventions
Albert Garcia‐Romeu, William A. Richards
International Review of Psychiatry (2018) Vol. 30, Iss. 4, pp. 291-316
Closed Access | Times Cited: 153
Awe: a putative mechanism underlying the effects of classic psychedelic-assisted psychotherapy
Peter S. Hendricks
International Review of Psychiatry (2018) Vol. 30, Iss. 4, pp. 331-342
Closed Access | Times Cited: 147
Making “bad trips” good: How users of psychedelics narratively transform challenging trips into valuable experiences
Liridona Gashi, Sveinung Sandberg, Willy Pedersen
International Journal of Drug Policy (2020) Vol. 87, pp. 102997-102997
Open Access | Times Cited: 124
Double-blind comparison of the two hallucinogens psilocybin and dextromethorphan: similarities and differences in subjective experiences
Theresa M. Carbonaro, Matthew W. Johnson, Ethan Hurwitz, et al.
Psychopharmacology (2017) Vol. 235, Iss. 2, pp. 521-534
Open Access | Times Cited: 116
5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) used in a naturalistic group setting is associated with unintended improvements in depression and anxiety
Alan K. Davis, Sara So, Rafael Lancelotta, et al.
The American Journal of Drug and Alcohol Abuse (2019) Vol. 45, Iss. 2, pp. 161-169
Open Access | Times Cited: 112
Pivotal mental states
Ari Brouwer, Robin Carhart‐Harris
Journal of Psychopharmacology (2020) Vol. 35, Iss. 4, pp. 319-352
Open Access | Times Cited: 112
From Egoism to Ecoism: Psychedelics Increase Nature Relatedness in a State-Mediated and Context-Dependent Manner
Hannes Kettner, Sam Gandy, Eline Haijen, et al.
International Journal of Environmental Research and Public Health (2019) Vol. 16, Iss. 24, pp. 5147-5147
Open Access | Times Cited: 110
The epidemiology of 5-methoxy-N, N-dimethyltryptamine (5-MeO-DMT) use: Benefits, consequences, patterns of use, subjective effects, and reasons for consumption
Alan K. Davis, Joseph P. Barsuglia, Rafael Lancelotta, et al.
Journal of Psychopharmacology (2018) Vol. 32, Iss. 7, pp. 779-792
Open Access | Times Cited: 109
Naturalistic Use of Mescaline Is Associated with Self-Reported Psychiatric Improvements and Enduring Positive Life Changes
Gabrielle Agin-Liebes, Trevor Forrest Haas, Rafael Lancelotta, et al.
ACS Pharmacology & Translational Science (2021) Vol. 4, Iss. 2, pp. 543-552
Open Access | Times Cited: 95
People of color in North America report improvements in racial trauma and mental health symptoms following psychedelic experiences
Monnica T. Williams, Alan K. Davis, Yitong Xin, et al.
Drugs Education Prevention and Policy (2020) Vol. 28, Iss. 3, pp. 215-226
Open Access | Times Cited: 77
Psychedelic Harm Reduction and Integration: A Transtheoretical Model for Clinical Practice
Ingmar Gorman, Elizabeth M. Nielson, Aja Molinar, et al.
Frontiers in Psychology (2021) Vol. 12
Open Access | Times Cited: 77
Optimal dosing for psilocybin pharmacotherapy: Considering weight-adjusted and fixed dosing approaches
Albert Garcia‐Romeu, Frederick S. Barrett, Theresa M. Carbonaro, et al.
Journal of Psychopharmacology (2021) Vol. 35, Iss. 4, pp. 353-361
Open Access | Times Cited: 72
Attitudes and Beliefs about the Therapeutic Use of Psychedelic Drugs among Psychologists in the United States
Alan K. Davis, Gabrielle Agin-Liebes, Megan España, et al.
Journal of Psychoactive Drugs (2021) Vol. 54, Iss. 4, pp. 309-318
Open Access | Times Cited: 69
Combining Psychedelic and Mindfulness Interventions: Synergies to Inform Clinical Practice
Jake Payne, Richard Chambers, Paul Liknaitzky
ACS Pharmacology & Translational Science (2021) Vol. 4, Iss. 2, pp. 416-423
Open Access | Times Cited: 66
Assessing the risk–benefit profile of classical psychedelics: a clinical review of second-wave psychedelic research
David A. Bender, David J. Hellerstein
Psychopharmacology (2022) Vol. 239, Iss. 6, pp. 1907-1932
Closed Access | Times Cited: 64
Study Protocol for “Psilocybin as a Treatment for Anorexia Nervosa: A Pilot Study”
Meg J. Spriggs, Hannah Douglass, Rebecca J. Park, et al.
Frontiers in Psychiatry (2021) Vol. 12
Open Access | Times Cited: 59
Drug-drug interactions between psychiatric medications and MDMA or psilocybin: a systematic review
Aryan Sarparast, Kelan Thomas, Benjamin Malcolm, et al.
Psychopharmacology (2022) Vol. 239, Iss. 6, pp. 1945-1976
Open Access | Times Cited: 52
Antidepressant effects of a psychedelic experience in a large prospective naturalistic sample
Victoria Amalie Nygart, Lis Marie Pommerencke, Eline Haijen, et al.
Journal of Psychopharmacology (2022) Vol. 36, Iss. 8, pp. 932-942
Open Access | Times Cited: 50
Adverse experiences resulting in emergency medical treatment seeking following the use of magic mushrooms
Emma I Kopra, Jason Ferris, Adam Winstock, et al.
Journal of Psychopharmacology (2022) Vol. 36, Iss. 8, pp. 965-973
Open Access | Times Cited: 45
The Acceptance/Avoidance-Promoting Experiences Questionnaire (APEQ): A theory-based approach to psychedelic drugs’ effects on psychological flexibility
Max Wolff, Lea J. Mertens, Marie Walter, et al.
Journal of Psychopharmacology (2022) Vol. 36, Iss. 3, pp. 387-408
Open Access | Times Cited: 40
Pattern breaking: a complex systems approach to psychedelic medicine
Inês Hipólito, Jonas Mago, Fernando E. Rosas, et al.
Neuroscience of Consciousness (2023) Vol. 2023, Iss. 1
Open Access | Times Cited: 39

Scroll to top